Join
Live feed
·
PRReleasevia Quantisnow
Arvinas Inc. logo
Pfizer Inc. logo

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)

ByQuantisnow·Wall Street's wire, on your screen.
ARVN· Arvinas Inc.PFE· Pfizer Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARVN (Arvinas Inc.), PFE (Pfizer Inc.) and more on Quantisnow.